Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Long-time Stryker chair steps down: John W. Brown is stepping down as chairman of Stryker's board of directors at the end of the year, when president and CEO Steve MacMillan will take on the additional title and responsibility. Brown has chaired the board since 1981 and was president and CEO of the company from 1977 to 2003. MacMillan took the top executive posts at Stryker in 2005. "This timing is consistent with my original goal of providing a 5-year overlap with Steve MacMillan," Brown said

You may also be interested in...



Sequenom Addresses Problems With Tainted Data; CEO Fired

Sequenom will rely on independent third-party validation of all future tests after an investigation into SEQureDX Down syndrome test R&D data revealed mishandling by employees

ArthroCare CEO Resigns As Inquiry Into Accounting, Billing Practices Expands

Veteran health care exec and ArthroCare board member David Fitzgerald will step in as acting CEO of the embattled surgical instrument maker now that former chief exec Michael Baker has resigned in the shadow of an accounting scandal and government investigations

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel